Russell Investments Group Ltd. Has $7.77 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Russell Investments Group Ltd. lowered its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 11.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 140,496 shares of the specialty pharmaceutical company's stock after selling 17,462 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.67% of ANI Pharmaceuticals worth $7,767,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. US Bancorp DE increased its position in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after purchasing an additional 531 shares during the period. KBC Group NV boosted its stake in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after purchasing an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $166,000. HighTower Advisors LLC bought a new stake in shares of ANI Pharmaceuticals during the third quarter worth approximately $222,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after buying an additional 412 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts have commented on the stock. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price for the company. StockNews.com cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Guggenheim reaffirmed a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Friday. Finally, Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $79.75.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares of the company's stock, valued at $5,526,799.20. This represents a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,200 shares of company stock worth $197,792. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Stock Up 1.2 %

Shares of ANIP stock traded up $0.83 during trading hours on Tuesday, hitting $69.55. 191,896 shares of the company were exchanged, compared to its average volume of 269,229. The company has a market capitalization of $1.51 billion, a PE ratio of -126.45 and a beta of 0.49. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.00. The business has a 50 day moving average of $62.71 and a two-hundred day moving average of $59.22. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.